In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DiagnoCure gets DxS' Scorpions for colorectal cancer test:

This article was originally published in Clinica

Executive Summary

Manchester, UK-based molecular diagnostics company DxS has licensed its Scorpions technology to Canada's DiagnoCure for use in the latter's colorectal cancer tests. Financial terms of the agreement were not disclosed. DxS' technology is said to be ideal for cancer tests as it employs probes that are highly sensitive and specific, thereby improving productivity and lowering the costs of processing the tests. DiagnoCure will use the technology to detect GC-C (guanylyl cyclase c), a gene that appears normally in cells lining the intestinal tract, but is found on the outside of the intestine when colorectal cancer has metastasised.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts